LONDON, Feb 1: Britain’s healthcare cost watchdog NICE said on Friday it was not able to recommend a new diabetes drug from Bristol-Myers Squibb and AstraZeneca, and has asked for more information from the companies. The National Institute for Health and Clinical Excellence (NICE) has been considering Forxiga, or dapagliflozin, as an add-on therapy for use with other medicines, including insulin.(agencies)